Adaptimmune Therapeutics plc (NASDAQ:ADAP) Receives $1.52 Average Price Target from Analysts
Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) have received a consensus recommendation of “Hold” from the seven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the […]
Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) have received a consensus recommendation of “Hold” from the seven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the […]
